What is the evidence that personalized, gene-directed cancer therapy, in which specific molecular drivers of a patient's disease are aligned with specific therapy, will improve outcomes?

What is the evidence that personalized, gene-directed cancer therapy, in which specific molecular drivers of a patient's disease are aligned with specific therapy, will improve outcomes?

What is the evidence that more personalized, gene-directed cancer therapy, in which specific molecular drivers of a patient’s disease are aligned with specific therapy, will improve patient outcomes? To what extent are they improved with targeted therapy, in breast, long (NSLC), and colorectal cancer?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Professsor Hyun Cheol Chung, MD

Professsor Hyun Cheol Chung, MD

Professor of Medical Oncology
Director, Yonsei Song-Dang Institute for Cancer Research
Yonsei University College of Medicine
Seoul, Korea